Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
Portfolio Pulse from
Rhythm Pharmaceuticals has received expanded marketing authorization in the UK for its drug IMCIVREE to treat obesity and hunger in patients with certain genetic conditions, now including children as young as 2 years old.
December 03, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rhythm Pharmaceuticals' drug IMCIVREE has received expanded marketing authorization in the UK, now approved for treating obesity and hunger in children as young as 2 with specific genetic conditions.
The expanded approval in the UK for IMCIVREE to include younger children broadens the potential market for Rhythm Pharmaceuticals, likely boosting sales and investor sentiment positively in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90